Tevogen Bio Holdings (TVGN) Preferred Stock Liabilities (2021 - 2023)

Tevogen Bio Holdings has reported Preferred Stock Liabilities for 3 years, with the latest figure at $16.7 million in Q4 2023.

• For the quarter ending Q4 2023, Preferred Stock Liabilities fell 95.33% year-over-year to $16.7 million; the trailing twelve-month figure through Dec 2023 stood at $16.7 million (down 95.33% YoY), and the FY2023 full-year result was $16.7 million, down 95.33% from the prior year.
• Preferred Stock Liabilities for Q4 2023 stood at $16.7 million, down from $26.0 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $356.9 million in Q4 2022, with the low at $16.7 million in Q4 2023.
• Historically, Preferred Stock Liabilities has averaged $206.7 million across 3 years, with a median of $351.9 million in 2021.
• Annual changes were most pronounced in 2022 — Preferred Stock Liabilities increased 1.41% — and 2023, when it sank 95.33%.
• Tevogen Bio Holdings' Preferred Stock Liabilities stood at $351.9 million in 2021, then rose by 1.41% to $356.9 million in 2022, then slumped by 95.33% to $16.7 million in 2023.
• The last three Preferred Stock Liabilities figures came in at $16.7 million (Q4 2023), $26.0 million (Q3 2023), and $25.7 million (Q2 2023), per Business Quant data.